ArticleDrug delivery and translational research2026
Development of a microneedle patch for delivery of mRNA-lipid nanoparticles.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipid Nanoparticles for Gene Therapy: Unresolved Challenges in Manufacturing, Transdermal Delivery, Machine Learning, Endosomal Escape, and the Protein Corona.Pharmaceutics · 2026Review
- Transdermal Delivery of an mRNA-Liposome Vaccine via Dissolving Microneedle to Preserve Vaccine Activity and Enhance Immune Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
mRNA delivered by microneedle patch (MNP) can enable painless delivery, reduced need for healthcare expertise, and improved thermostability. In this study, we investigated formulation and manufacturing approaches for developing MNPs that deliver mRNA-loaded lipid nanoparticles (LNPs) encoding luciferase as a reporter protein during MNP fabrication and storage, including mRNA-LNP concentration, formulation, pH, excipients, and backing material. MNPs were assessed for mRNA-LNP size, encapsulation efficiency, and protein expression in vitro and in vivo. MNPs fabricated with mRNA-LNPs initially prepared at a higher concentration yielded superior expression compared to mRNA-LNP concentration by centrifugation or tangential flow filtration. Acidic pH during MNP manufacturing enabled greater expression in vitro. However, no such correlation was observed in vivo. Polyvinyl alcohol (PVA) best stabilized mRNA-LNPs during the MNP manufacturing process amongst the tested polymers. Incorporating sugars in MNPs did not further improve stability. Low temperature drying (5 °C) preserved mRNA functionality better compared to drying at 25 °C and 40 °C. Though there was significant activity loss initially (87% loss in 2 days at 40 °C), mRNA expression was stabilized for extended subsequent periods even at accelerated conditions (10% additional loss after 28 days at 40 °C). Our systematic approach identified key parameters for successful formulation and manufacturing approaches to incorporate mRNA-LNPs into MNPs, which could expand access to mRNA-based medical interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.